MX339146B - Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos. - Google Patents

Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.

Info

Publication number
MX339146B
MX339146B MX2012006987A MX2012006987A MX339146B MX 339146 B MX339146 B MX 339146B MX 2012006987 A MX2012006987 A MX 2012006987A MX 2012006987 A MX2012006987 A MX 2012006987A MX 339146 B MX339146 B MX 339146B
Authority
MX
Mexico
Prior art keywords
homogeneous suspension
immunopotentiating compounds
immunopotentiating
compounds
homogeneous suspensions
Prior art date
Application number
MX2012006987A
Other languages
English (en)
Other versions
MX2012006987A (es
Inventor
Derek O'hagan
Manmohan Singh
Siddhartha Jain
David Skibinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012006987A publication Critical patent/MX2012006987A/es
Publication of MX339146B publication Critical patent/MX339146B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere en general a suspensiones homogéneas de inmunopotenciadores de molécula pequeña (SMPI) que son capaces de estimular o modular una respuesta inmunitaria en un sujeto en necesidad de lo mismo. Las suspensiones homogéneas se pueden usar en combinación con varios antígenos o adyuvantes para terapias de vacuna.
MX2012006987A 2009-12-15 2010-12-15 Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos. MX339146B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28675409P 2009-12-15 2009-12-15
PCT/US2010/060621 WO2011084549A1 (en) 2009-12-15 2010-12-15 Homogeneous suspension of immunopotentiating compounds and uses thereof

Publications (2)

Publication Number Publication Date
MX2012006987A MX2012006987A (es) 2012-07-17
MX339146B true MX339146B (es) 2016-05-13

Family

ID=43920779

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006987A MX339146B (es) 2009-12-15 2010-12-15 Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.

Country Status (11)

Country Link
US (2) US9408907B2 (es)
EP (1) EP2512478B1 (es)
JP (2) JP5814933B2 (es)
CN (1) CN102762206A (es)
AU (1) AU2010339921B2 (es)
BR (1) BR112012014624A8 (es)
CA (1) CA2784580A1 (es)
ES (1) ES2631977T3 (es)
MX (1) MX339146B (es)
SG (2) SG10201501980SA (es)
WO (1) WO2011084549A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502631A1 (en) * 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
MX2015005306A (es) * 2012-10-25 2015-07-17 Glaxosmithkline Biolog Sa Nicotinamida como adyuvante.
CN103784966B (zh) * 2014-01-23 2016-03-23 广东省农业科学院动物卫生研究所 羧甲基纤维素钠在鸡球虫活卵囊疫苗中的应用
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2017076873A1 (en) * 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
CN106045902A (zh) * 2016-06-30 2016-10-26 苏州健雄职业技术学院 一种3‑溴‑6‑甲基‑2‑吡啶甲醛的制备方法
GB202215414D0 (en) * 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4726912A (en) * 1986-08-27 1988-02-23 Phillips Petroleum Company Stable suspensions of carboxymethyl cellulose and their preparation
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
WO1997037026A1 (en) 1996-04-02 1997-10-09 Smithkline Beecham Corporation Novel compounds
EP0914330A4 (en) 1996-05-14 2002-01-09 Smithkline Beecham Corp NEW TYPE COMPOUNDS
US6420135B1 (en) 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
AU755462B2 (en) 1997-08-21 2002-12-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
CA2310217A1 (en) 1997-11-26 1999-06-03 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
EP1073450A4 (en) 1998-04-23 2003-04-23 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C (PSPC), EPITOPIC REGIONS, SELECTION OF CORRESPONDING STRES AND USES
JP5102414B2 (ja) 1998-05-01 2012-12-19 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 髄膜炎菌抗原および組成物
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
JP2002531055A (ja) 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌のタンパク質及び核酸分子
CN1318103A (zh) 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
CA2341018C (en) 1998-08-31 2012-07-31 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
ES2322409T3 (es) 1998-08-31 2009-06-19 Inhibitex, Inc. Vacunas multicomponentes contra staphylococcus aureus.
EP1144998A3 (en) 1998-10-09 2002-08-07 Chiron Corporation Neisseria genomic sequences and methods of their use
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
EP1140157B1 (en) 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
JP4785014B2 (ja) 1999-03-26 2011-10-05 プロヴァリス・ユーケー・リミテッド 蛋白質
DE60045721D1 (de) 1999-06-10 2011-04-21 Medimmune Inc Streptococcus pneumoniae Proteine und Impfstoffe
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
CN1416352B (zh) 2000-01-17 2011-05-25 启龙股份公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
MXPA02008314A (es) 2000-02-28 2002-12-09 Chiron Spa Expresion heterologa de proteinas de neisseria.
CA2404260A1 (en) 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
US6689369B2 (en) 2000-04-27 2004-02-10 Medimmune, Inc. Immunogenic pneumococcal protein and vaccine compositions thereof
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
US6495079B1 (en) 2000-06-28 2002-12-17 Prisma Fibers, Inc. Process to prepare polymeric fibers with improved color and appearance
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
WO2002008426A2 (en) 2000-07-20 2002-01-31 Hansa Medical Ab Fh-binding protein of streptococcus pneumoniae
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP1330473A2 (en) 2000-10-26 2003-07-30 Imperial College Innovations Limited Streptococcal genes
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0108079D0 (en) 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
ATE557041T1 (de) 2001-05-18 2012-05-15 Us Gov Health & Human Serv Peptid-vakzinen gegen streptokokken der gruppe a
EP2320233A1 (en) 2001-06-15 2011-05-11 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
CA2453937C (en) 2001-08-02 2013-05-14 University Of Sheffield Antigenic polypeptides
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
WO2003082183A2 (en) 2002-04-02 2003-10-09 Ben-Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
EP1511768B1 (en) 2002-06-11 2007-04-11 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP1551357B1 (en) 2002-09-13 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus vaccine
CA2501812C (en) 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
MXPA05006367A (es) * 2002-12-12 2005-08-29 Pharmacia Corp Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
EP2333114A1 (en) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
MXPA05013260A (es) 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
PL1648500T3 (pl) 2003-07-31 2014-12-31 Novartis Vaccines & Diagnostics Inc Kompozycje immunogenne dla Streptococcus pyogenes
EP1725575B1 (en) 2004-02-18 2012-11-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
HUE033196T2 (en) 2005-01-27 2017-11-28 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
JP2009521707A (ja) 2005-12-27 2009-06-04 オーベテック， エルエルシー 疾患のバイオマーカーとしての脂肪生成アデノウイルス
CA2637598A1 (en) 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
JP2009538116A (ja) 2006-02-17 2009-11-05 ノバルティス アーゲー 細菌抗原の精製
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
CN101422437A (zh) * 2008-11-14 2009-05-06 李铁军 一种依托泊苷干混悬剂及其制备方法
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
AU2010288240B2 (en) 2009-08-27 2014-03-27 Novartis Ag Hybrid polypeptides including meningococcal fHBP sequences
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物

Also Published As

Publication number Publication date
SG10201501980SA (en) 2015-05-28
CA2784580A1 (en) 2011-07-14
JP5814933B2 (ja) 2015-11-17
BR112012014624A8 (pt) 2017-12-26
EP2512478A1 (en) 2012-10-24
AU2010339921A1 (en) 2012-07-12
EP2512478B1 (en) 2017-04-19
US20130101629A1 (en) 2013-04-25
CN102762206A (zh) 2012-10-31
JP2015134828A (ja) 2015-07-27
BR112012014624A2 (pt) 2016-03-01
JP2013514382A (ja) 2013-04-25
AU2010339921B2 (en) 2016-08-11
US10046048B2 (en) 2018-08-14
US20160375132A1 (en) 2016-12-29
MX2012006987A (es) 2012-07-17
ES2631977T3 (es) 2017-09-07
WO2011084549A1 (en) 2011-07-14
SG181712A1 (en) 2012-07-30
US9408907B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
MX2012006987A (es) Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
GB0917002D0 (en) Improved shigella blebs
CL2016003172A1 (es) Anticuerpos dirigidos contra cd127
IN2015DN02826A (es)
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
WO2010062322A3 (en) Modulation of the immune response
WO2008116078A3 (en) Stimulation of an immune response by cationic lipids
WO2010033274A3 (en) Nanoemulsion adjuvants
IN2014CN00688A (es)
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
SG10201900041VA (en) Meningococcus vaccines
EP4218809A3 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
GB201017519D0 (en) Vaccines
AU2014225575A8 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
MY172699A (en) Implantable medical devices with increased immune tolerance, and methods for making and implanting
TWD178855S (zh) 電連接器
MX2016013631A (es) Celulas huespedes modificadas y usos de las mismas.
MX2010004892A (es) Terapia de combinacion para tratar infecciones virales persistentes.
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
WO2012003361A3 (en) Nanoemulsion vaccines
WO2019099578A8 (en) Use of imidazopyrimidine for modulating human immune response
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
EP3648639A4 (en) IMPROVED BED MATERIAL WITH LOCKING PIN FIXING ARRANGEMENT

Legal Events

Date Code Title Description
FG Grant or registration